Key result
Ivabradine was less effective than carvedilol at reducing chamber dilatation, cardiac fibrosis, and atrial fibrillation inducibility in a rat model of mitral regurgitation (P<0.05).
Why the study?
Studies comparing the effects of ivabradine and beta-blockers on mitral regurgitation are lacking.
Does ivabradine compared to carvedilol improve cardiac remodeling and reduce atrial fibrillation in a rat model of mitral regurgitation?
RCT
randomized
Does ivabradine compared to carvedilol improve cardiac remodeling and reduce atrial fibrillation in a rat model of mitral regurgitation?
p-value: p=<0.05
In a rat model of mitral regurgitation, carvedilol was superior to ivabradine in mitigating cardiac fibrosis, apoptosis, and atrial fibrillation inducibility.
No takes yet. Share an insight, caveat, or question.
No immediate clinical implications from this animal study; leaves open differential effects of ivabradine versus carvedilol in human mitral regurgitation.
Lee et al. (2023) conducted an RCT in Mitral regurgitation. Ivabradine vs. Carvedilol was evaluated on Chamber dilatation, compliance, and atrial fibrillation inducibility (p=<0.05). Ivabradine was less effective than carvedilol at reducing chamber dilatation, cardiac fibrosis, and atrial fibrillation inducibility in a rat model of mitral regurgitation (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: